Sign up to save your podcasts
Or
Share No pain, no gain: Ozempic’s quest for market share
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.2
4646 ratings
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Viewsroom
View all
Global News Podcast
7,807 Listeners
Economist Podcasts
4,181 Listeners
Business Daily
531 Listeners
WSJ What’s News
4,395 Listeners
World Business Report
299 Listeners
Bloomberg Businessweek
438 Listeners
The Big View
34 Listeners
WSJ Minute Briefing
682 Listeners
FT News Briefing
650 Listeners
The World in Brief from The Economist
1,081 Listeners
Wall Street Week
65 Listeners
Reuters World News
307 Listeners
WSJ's Take On the Week
149 Listeners
The Economics Show
150 Listeners
Reuters Econ World
27 Listeners